CN1172719C - 单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂 - Google Patents

单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂 Download PDF

Info

Publication number
CN1172719C
CN1172719C CNB008067783A CN00806778A CN1172719C CN 1172719 C CN1172719 C CN 1172719C CN B008067783 A CNB008067783 A CN B008067783A CN 00806778 A CN00806778 A CN 00806778A CN 1172719 C CN1172719 C CN 1172719C
Authority
CN
China
Prior art keywords
group
retinopathy
angiotensin
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008067783A
Other languages
English (en)
Chinese (zh)
Other versions
CN1348385A (zh
Inventor
�кӾ�֦
中河静枝
渚康贵
池田衡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN1348385A publication Critical patent/CN1348385A/zh
Application granted granted Critical
Publication of CN1172719C publication Critical patent/CN1172719C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB008067783A 1999-04-28 2000-04-27 单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂 Expired - Fee Related CN1172719C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP121498/1999 1999-04-28
JP121498/99 1999-04-28
JP12149899 1999-04-28

Publications (2)

Publication Number Publication Date
CN1348385A CN1348385A (zh) 2002-05-08
CN1172719C true CN1172719C (zh) 2004-10-27

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008067783A Expired - Fee Related CN1172719C (zh) 1999-04-28 2000-04-27 单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂

Country Status (23)

Country Link
US (2) US7064141B1 (enExample)
EP (1) EP1197223B1 (enExample)
KR (1) KR100865059B1 (enExample)
CN (1) CN1172719C (enExample)
AT (1) ATE289204T1 (enExample)
AU (1) AU774799B2 (enExample)
BR (1) BR0010084A (enExample)
CA (1) CA2371554C (enExample)
CZ (1) CZ301913B6 (enExample)
DE (1) DE60018186T2 (enExample)
DK (1) DK1197223T3 (enExample)
ES (1) ES2233362T3 (enExample)
HU (1) HU226948B1 (enExample)
MX (1) MXPA01010923A (enExample)
NO (1) NO327446B1 (enExample)
NZ (1) NZ514855A (enExample)
PL (1) PL196895B1 (enExample)
PT (1) PT1197223E (enExample)
RU (1) RU2239454C2 (enExample)
SI (1) SI1197223T1 (enExample)
SK (1) SK286859B6 (enExample)
WO (1) WO2000066161A1 (enExample)
ZA (1) ZA200108527B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
ES2535291T3 (es) * 2003-04-15 2015-05-08 Daiichi Sankyo Company, Limited Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
ES2425750T3 (es) 2004-08-31 2013-10-17 Newsouth Innovations Pty Limited Inhibición del VEGF
PL1814527T5 (pl) * 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
RU2420280C2 (ru) * 2005-04-21 2011-06-10 Сантен Фармасьютикал Ко., Лтд Терапевтическое средство против кератоконъюнктивального расстройства
KR20080074128A (ko) * 2005-12-06 2008-08-12 산텐 세이야꾸 가부시키가이샤 각결막 장애 치료제
TWI415634B (zh) * 2007-03-28 2013-11-21 Takeda Pharmaceutical 固態醫藥組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027211D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
UA49880C2 (uk) * 1996-03-29 2002-10-15 Смітклайн Бічам Корпорейшн Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
TW416953B (en) * 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP4475685B2 (ja) * 1997-06-27 2010-06-09 スミスクライン・ビーチャム・コーポレイション エプロサルタン・一水和物
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
ATE341325T1 (de) * 1997-08-06 2006-10-15 Smithkline Beecham Corp Eprosartan arginyl-ladungsneutralisationskomplex und verfahren zu dessen herstellung und verabreichung
WO1999044590A1 (en) 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
KR20040078140A (ko) * 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
JP2000159671A (ja) 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Also Published As

Publication number Publication date
ES2233362T3 (es) 2005-06-16
WO2000066161A1 (en) 2000-11-09
US20060189669A1 (en) 2006-08-24
SI1197223T1 (enExample) 2005-08-31
NO20015257L (no) 2001-10-26
PL350554A1 (en) 2002-12-16
PL196895B1 (pl) 2008-02-29
ZA200108527B (en) 2002-10-17
HU226948B1 (en) 2010-03-29
BR0010084A (pt) 2002-01-15
EP1197223A1 (en) 2002-04-17
CA2371554A1 (en) 2000-11-09
DE60018186D1 (de) 2005-03-24
EP1197223B1 (en) 2005-02-16
SK15452001A3 (sk) 2002-04-04
SK286859B6 (sk) 2009-06-05
US7064141B1 (en) 2006-06-20
CA2371554C (en) 2009-06-09
ATE289204T1 (de) 2005-03-15
RU2239454C2 (ru) 2004-11-10
DE60018186T2 (de) 2005-12-29
NO327446B1 (no) 2009-06-29
AU4143400A (en) 2000-11-17
HUP0200890A3 (en) 2002-12-28
NZ514855A (en) 2004-01-30
DK1197223T3 (da) 2005-05-30
CZ301913B6 (cs) 2010-07-28
NO20015257D0 (no) 2001-10-26
CZ20013804A3 (cs) 2002-04-17
AU774799B2 (en) 2004-07-08
HUP0200890A2 (hu) 2002-11-28
KR100865059B1 (ko) 2008-10-23
KR20020015315A (ko) 2002-02-27
PT1197223E (pt) 2005-04-29
MXPA01010923A (es) 2002-06-21
CN1348385A (zh) 2002-05-08
EP1197223A4 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
CN1404390A (zh) TNF－α抑制剂
CN1615134A (zh) 含有缬沙坦和nep抑制剂的药物组合物
CN1081460C (zh) 醛糖还原酶抑制剂用于制备减少与非心脏局部缺血有关的组织损伤的药物的用途
JP2016094436A (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
CN1323200A (zh) 5ht4激动剂或拮抗剂的新型口服制剂
EP2716302B1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
RU2239454C2 (ru) Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии
US10537563B2 (en) Methods for treating ocular disease using inhibitors of CSF-1R
JP2000159671A (ja) 血管新生阻害剤
JP4276768B2 (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
JPH0867674A (ja) 眼圧降下剤
JP2002212101A (ja) 歯肉肥厚抑制剤
EP1579872B1 (en) Body weight gain inhibitor
JPWO2006046528A1 (ja) 糸球体疾患治療剤
JPWO2000066161A1 (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
CN1501802A (zh) 芳基乙烯磺酰胺衍生物的新用途
TW200934484A (en) A medicament for the prevention or treatment of diseases accompanied with the hyperfunction of permeability of ocular blood vessels
JP2007077095A (ja) 腫瘍治療方法および抗腫瘍剤
CN1499971A (zh) 芳基乙烯磺酰胺衍生物的新用途
HK1083587B (en) Body weight gain inhibitor
CN1878550A (zh) 用于识别改进的非镇静α－2激动剂的方法

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041027

Termination date: 20110427